Covant Therapeutics
Ronald Tomlinson is an experienced professional in chemical biology and target identification, currently serving as a Fellow at Covant Therapeutics since September 2022, following a brief tenure in the same role at Roivant Discovery from April to September 2022. Prior experience includes positions as Principal Scientist at Cedilla Therapeutics, Associate Principal Scientist at AstraZeneca, Senior Research Investigator at Sanofi focused on target identification using small molecules, and various research roles at Novartis, Vertex Pharmaceuticals, SIBIA Neurosciences, Hoechst Marion Roussel, and Marion Merrell Dow. Ronald holds a BS and MS in Chemistry from Wright State University, with academic guidance from James Kane, PhD.
This person is not in any teams
Covant Therapeutics
Operator of a covalent drug discovery company intended to create novel therapeutics by using covalency to imprint and regulate proteins. The company applies cutting-edge capabilities and expertise in chemistry, quantitative proteomics, translational sciences, and deep learning, enabling clients to translate discoveries into drugs.